Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM Study)
Phase of Trial: Phase I/II
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Allogeneic bone marrow derived mesenchymal stromal cell therapy Orbsen Therapeutics (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions; First in man
- Acronyms NEPHSTROM
- 31 Aug 2018 Biomarkers information updated
- 16 Mar 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Jun 2020.
- 16 Mar 2018 Status changed from not yet recruiting to recruiting.